Stock Research: Hanmi Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Hanmi Pharmaceutical

KOSE:A128940 KR7128940004
27
  • Value
    8
  • Growth
    98
  • Safety
    Safety
    14
  • Combined
    22
  • Sentiment
    49
  • 360° View
    360° View
    27
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Hanmi Pharm Co Ltd manufactures and sells pharmaceuticals. It operates in the pharmaceuticals and materials processing industries, and exports its products. In the last fiscal year, the company had a market cap of $2,625 million, profits of $553 million, and revenue of $1,013 million. There is no data for the number of employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 27 (better than 27% compared with alternatives), overall professional sentiment and financial characteristics for the stock Hanmi Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Hanmi Pharmaceutical. The consolidated Growth Rank has a good rank of 98, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 98% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 14 means that the share price of Hanmi Pharmaceutical is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 86% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 8, which means that the company has a riskier financing structure than 92% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 49, indicating professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. ...read more

more
Index
Low Emissions
Energy Efficient
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
14 16 14 15
Growth
98 72 91 91
Safety
Safety
8 10 10 1
Sentiment
49 72 96 39
360° View
360° View
27 10 49 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
75 81 67 76
Opinions Change
17 32 75 42
Pro Holdings
n/a 70 74 12
Market Pulse
69 63 72 56
Sentiment
49 72 96 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
14 16 14 15
Growth
98 72 91 91
Safety Safety
8 10 10 1
Combined
22 1 27 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
22 30 26 14
Price vs. Earnings (P/E)
16 28 30 39
Price vs. Book (P/B)
13 19 12 14
Dividend Yield
24 20 22 17
Value
14 16 14 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
62 61 61 52
Profit Growth
69 56 85 100
Capital Growth
90 90 75 88
Stock Returns
98 28 63 27
Growth
98 72 91 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
27 23 9 2
Refinancing
4 14 9 5
Liquidity
34 75 28 16
Safety Safety
8 10 10 1

Similar Stocks

Discover high‑ranked alternatives to Hanmi Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

NH Investment & Securities

KOSE:A005940
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Medium
Full Stock Analysis

KT

KOSE:A030200
Country: South Korea
Industry: Integrated Telecommunication
Size: Large
Full Stock Analysis

Hankook Tire

KOSE:A161390
Country: South Korea
Industry: Tires & Rubber
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.